162 related articles for article (PubMed ID: 36982681)
21. IL-17A/IL-17RA interaction promoted metastasis of osteosarcoma cells.
Wang M; Wang L; Ren T; Xu L; Wen Z
Cancer Biol Ther; 2013 Feb; 14(2):155-63. PubMed ID: 23192273
[TBL] [Abstract][Full Text] [Related]
22. The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis.
Liu JY; Zhu BR; Wang YD; Sun X
Int J Clin Oncol; 2020 Jun; 25(6):1195-1205. PubMed ID: 32215805
[TBL] [Abstract][Full Text] [Related]
23. Establishment of an Autophagy-Related Clinical Prognosis Model for Predicting the Overall Survival of Osteosarcoma.
Li J; Tang X; Du Y; Dong J; Zhao Z; Hu H; Song T; Guo J; Wang Y; Xu T; Shao C; Sheng Y; Xi Y
Biomed Res Int; 2021; 2021():5428425. PubMed ID: 34604383
[TBL] [Abstract][Full Text] [Related]
24. Expression of MSH2 and MSH6 on a tissue microarray in patients with osteosarcoma.
Jentzsch T; Robl B; Husmann M; Bode-Lesniewska B; Fuchs B
Anticancer Res; 2014 Dec; 34(12):6961-72. PubMed ID: 25503122
[TBL] [Abstract][Full Text] [Related]
25. Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma.
He C; Liu C; Wang L; Sun Y; Jiang Y; Hao Y
Cell Death Dis; 2019 Jan; 10(2):65. PubMed ID: 30683853
[TBL] [Abstract][Full Text] [Related]
26. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents.
Buddingh EP; Kuijjer ML; Duim RA; Bürger H; Agelopoulos K; Myklebost O; Serra M; Mertens F; Hogendoorn PC; Lankester AC; Cleton-Jansen AM
Clin Cancer Res; 2011 Apr; 17(8):2110-9. PubMed ID: 21372215
[TBL] [Abstract][Full Text] [Related]
27. Research Progress of MicroRNA in Chemotherapy Resistance of Osteosarcoma.
Tang Z; Lu Y; Chen Y; Zhang J; Chen Z; Wang Q
Technol Cancer Res Treat; 2021; 20():15330338211034262. PubMed ID: 34323141
[TBL] [Abstract][Full Text] [Related]
28. Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcoma.
Hattinger CM; Serra M
Expert Opin Drug Metab Toxicol; 2015; 11(9):1449-63. PubMed ID: 26095223
[TBL] [Abstract][Full Text] [Related]
29. A long non-coding RNA contributes to doxorubicin resistance of osteosarcoma.
Zhang CL; Zhu KP; Shen GQ; Zhu ZS
Tumour Biol; 2016 Feb; 37(2):2737-48. PubMed ID: 26408180
[TBL] [Abstract][Full Text] [Related]
30. Role of ezrin in osteosarcoma metastasis.
Ren L; Khanna C
Adv Exp Med Biol; 2014; 804():181-201. PubMed ID: 24924175
[TBL] [Abstract][Full Text] [Related]
31. Loss of MicroRNA-489-3p promotes osteosarcoma metastasis by activating PAX3-MET pathway.
Liu Q; Yang G; Qian Y
Mol Carcinog; 2017 Apr; 56(4):1312-1321. PubMed ID: 27859625
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA‑22 inhibits the proliferation and migration, and increases the cisplatin sensitivity, of osteosarcoma cells.
Zhou X; Natino D; Zhai X; Gao Z; He X
Mol Med Rep; 2018 May; 17(5):7209-7217. PubMed ID: 29568877
[TBL] [Abstract][Full Text] [Related]
33. Silencing of CD44 gene expression in human 143-B osteosarcoma cells promotes metastasis of intratibial tumors in SCID mice.
Gvozdenovic A; Arlt MJ; Campanile C; Brennecke P; Husmann K; Born W; Muff R; Fuchs B
PLoS One; 2013; 8(4):e60329. PubMed ID: 23565227
[TBL] [Abstract][Full Text] [Related]
34. Macrophage-derived CCL18 promotes osteosarcoma proliferation and migration by upregulating the expression of UCA1.
Su Y; Zhou Y; Sun YJ; Wang YL; Yin JY; Huang YJ; Zhang JJ; He AN; Han K; Zhang HZ; Yao Y; Lv XB; Hu HY
J Mol Med (Berl); 2019 Jan; 97(1):49-61. PubMed ID: 30426155
[TBL] [Abstract][Full Text] [Related]
35. CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcoma.
Gao Y; Feng Y; Shen JK; Lin M; Choy E; Cote GM; Harmon DC; Mankin HJ; Hornicek FJ; Duan Z
Sci Rep; 2015 Jun; 5():11365. PubMed ID: 26079799
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-99b predicts clinical outcome of osteosarcoma and suppresses tumor cell proliferation, migration and invasion.
Shi X; Guan X
Diagn Pathol; 2019 Oct; 14(1):117. PubMed ID: 31651329
[TBL] [Abstract][Full Text] [Related]
37. Osteosarcoma transcriptome data exploration reveals STC2 as a novel risk indicator in disease progression.
Wang Z; Zeng Z; Gao F; Gui Z; Du J; Shen N; Shang Y; Yang Z; Shang L; Wei R; Ma W; Wang C
BMC Med Genomics; 2023 Feb; 16(1):30. PubMed ID: 36803385
[TBL] [Abstract][Full Text] [Related]
38. High expression of ABCG2 is associated with chemotherapy resistance of osteosarcoma.
Shu H; Yuan B; Huang Y; Wang L; He B; Sun Q; Sun L
J Orthop Surg Res; 2021 Jan; 16(1):85. PubMed ID: 33509236
[TBL] [Abstract][Full Text] [Related]
39. Osteosarcoma is characterised by reduced expression of markers of osteoclastogenesis and antigen presentation compared with normal bone.
Endo-Munoz L; Cumming A; Sommerville S; Dickinson I; Saunders NA
Br J Cancer; 2010 Jun; 103(1):73-81. PubMed ID: 20551950
[TBL] [Abstract][Full Text] [Related]
40. miR-382 inhibits osteosarcoma metastasis and relapse by targeting Y box-binding protein 1.
Xu M; Jin H; Xu CX; Sun B; Song ZG; Bi WZ; Wang Y
Mol Ther; 2015 Jan; 23(1):89-98. PubMed ID: 25292190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
